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capsid containing two copies of the 9032 base-pair RNASuzanne Beckham Shuker,* Victoria L. Mariani,
Bryan E. Herger, and Kelly J. Dennison genome [11]. It is made up of the genes gag, pro, pol,
and env flanked by long terminal repeats on each end,School of Chemistry and Biochemistry
Georgia Institute of Technology and expression of the genome yields Gag and Gag-Pro-
Pol polyprotein precursors [12, 13]. HTLV-I protease isAtlanta, Georgia 30332
encoded in a different reading frame than the Gag pre-
cursor and spans from the 3 end of the gag region to
the 5 end of pol region. Synthesis of the protease occursHuman T cell leukemia virus type I (HTLV-I) is a human
by ribosomal frameshifting [14], and a second ribosomalretrovirus that has been clinically associated with adult
frameshift produces the 95 kDa Pol polyprotein. UponT cell leukemia/lymphoma, and it has been designated
viral maturation, the retroviral protease (PR) cleaves theas a dangerous emerging pathogen by the Centers for
55 kDa Gag precursor into the matrix (MA), capsid (CA),Disease Control. Like other retroviruses, proteolytic
and nucleocapsid (NC) proteins. The Pol polyprotein isprocessing of specific sites in polyprotein precursors
cleaved into reverse transcriptase/RNase H (RT-RH) andby a retroviral protease is an essential step in the viral
integrase (IN). Because of its essential role in viral repli-life cycle. HTLV-I protease is a 28 kDa homodimeric
cation, HTLV-I protease is an attractive target for theaspartic acid protease that has only modest homology
development of inhibitors to treat HTLV-I infection. How-to other retroviral proteases. The enzymology of HTLV-I
ever, it has received little attention compared to its moreprotease has only recently begun to be investigated,
famous cousin HIV protease, which has been studiedand although it shares many characteristics of other
extensively. This review details what is known about theretroviral proteases, it exhibits distinct substrate
activity, specificity, and inhibition of HTLV-I protease.specificity and different susceptibility to aspartic acid
protease inhibitors. This review describes what has
been reported to date on the structural characteriza-
Retroviral Aspartic Acid Proteasestion, specificity, and inhibition of HTLV-I protease.
Cellular aspartic proteases, which are grouped in the
A1 family of aspartic proteases, contain two aspartic
Introduction acids in a highly conserved Asp-Thr/Ser-Gly motif. The
Human T cell leukemia virus type I (HTLV-I) is an oncovi- three-dimensional structures for members of the A1
rus in the Retroviridae family [1]. HTLV-I was the first family reveal that they are bilobed, pseudodimeric mo-
human retrovirus to be discovered and was isolated in nomers in which the lobes have similar structures. Ret-
the early 1980’s from patients with adult T cell leukemia/ roviral proteases were quickly classified as a new family
lymphoma (ATL) [2]. It was subsequently shown to be of aspartic proteases, the A2 family, when their primary
clinically associated with ATL [3], tropical spastic para- sequences were reported [15, 16]. However, retroviral
paresis/HTLV-I-associated myelopathy (TSP/HAM) [4], proteases are much smaller than their cellular counter-
and a number of chronic diseases, including uveitis, parts, such as pepsin, and their sequences contain only
arthritis, and infective dermatitis [5, 6]. HTLV-I infections one Asp-Thr-Gly motif. It was postulated, therefore, that
are endemic in high-risk groups in Melanesia, Japan, the retroviral proteases are symmetric homodimers and this
Caribbean, sub-Saharan Africa, and the United States. was confirmed upon structure elucidation. Structures
Currently, it is estimated that 15 to 20 million individuals have been determined for the proteases from HIV-1,
worldwide are infected with HTLV-I, and up to 10% of HIV-2, simian immunodeficiency virus (SIV), feline immu-
these infected individuals will develop ATL or TSP/HAM nodeficiency virus (FIV), equine infectious anemia virus
[6, 7]. The observation that Caribbean strains of HTLV-I (EIAV), and Rous sarcoma virus (RSV). From these struc-
are more easily transmitted and cause disease at a much tures, it can be seen that the dimer is held together by
earlier age than Japanese strains suggests that HTLV-I a four-stranded antiparallel  sheet involving the amino
may be evolving into a much more dangerous virus, and and carboxyl termini of each monomer. They contain
the Centers for Disease Control have recently desig- one active site that is formed at the dimer interface using
nated HTLV-I as a dangerous emerging pathogen [8, 9]. residues from each monomer. The active site is located
Based on its molecular organization and structure, in a cleft above the dimer interface, with the catalytic
HTLV-I has been taxonomically grouped in the delatvirus aspartyl residues positioned in a loop on the floor of the
genus of retroviruses with HTLV-II, primate T cell leuke- cleft. The top of the cleft is formed by a  sheet containing
mia virus (PTLV), and bovine leukemia virus (BLV) [10]. a -turn, referred to as “the flap,” from each monomer.
The mature type C virion is spherical and has a diameter These features can be seen in one of the published
of 110 to 140 nm. The host cell-derived viral membrane structures of HIV-1 protease, shown in Figure 1 [17].
contains two glycoproteins, a 21 kDa transmembrane Most of the structural studies of retroviral proteases
protein (TM) and a 46 kDa membrane surface glycopro- have been on HIV-1 protease with bound inhibitor. Pep-
tein (SU), encoded by the viral env gene. The center of tidic inhibitors bind in a  sheet conformation, so it has
the HTLV-I virion consists of a dense, spherical nucleo- been inferred that substrates bind in a similar manner.
Typically, a peptide must be at least seven amino acids
long to be recognized as a substrate. Following conven-*Correspondence: suzy.shuker@chemistry.gatech.edu
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in substrate specificity among the retroviral proteases.
The substrates are predominantly hydrophobic, and, al-
though there are some differences observed between
different proteases, examination of the substrate se-
quences (Table 1) reveals some trends. For example,
while there is variability in the P4 position among differ-
ent proteases, there is similarity among substrates for
a single protease. Proline is prevalent in HTLV-I and BLV
substrates, while serine and threonine are common in
MuLV and HIV-1 substrates. The P4 position is usually
hydrophobic, but the identities of the side chains found
in this position show no patterns. The P3 and P3 posi-
tions show great variability, and the handful of charged
residues found in the natural substrates are most often
Figure 1. Structure of HIV-1 Protease accommodated in these positions. Large hydrophobic
One monomer is colored blue and the other is colored magenta. amino acids are prevalent in the P2 and P2 positions,
The catalytic aspartic acids are highlighted in green. with leucine, isoleucine, and valine being the most com-
mon. The P1 and P1 positions are also predominantly
hydrophobic, and no charged residues are observed at
tion, the amino acids toward the amino terminus of the these positions in any of the natural substrates that have
substrate are numbered P1 to P4, with P1 being adjacent been identified to date. The P1 amino acid is most often
to the scissile bond, and those toward the carboxyl a leucine, and -branched side chains are not accom-
terminus are numbered P1 to P4. Retroviral proteases modated in the S1 subsite. On the other hand, side
have eight binding pockets that accommodate the side chains with a -branch are found in the P1 position in
chains of the substrate, and these subsites are num- some substrates, but the most common amino acid is
bered S1 to S4 and S1 to S4 to indicate which substrate proline. The substrates and subsites of HTLV-I protease,
residue is bound within the subsite. The strongest inter- in particular, will be discussed in greater detail in the
actions occur between the S3 to S3 subsites and the next section.
P3 to P3 side chains, while the S4/P4 and S4/P4 inter-
actions are much weaker. In addition to the contacts
between the subsites and the substrate side chains, HTLV-I Protease
HTLV-I protease was identified and isolated in the latethe protease also forms specific interactions with the
backbone of the substrate. The side chain interactions 1980’s [18]. Recombinant protease has been expressed
in E. coli, and it correctly processes HTLV-I Gag pol-confer specificity to the protease, while the interactions
with the backbone provide the proper orientation of the yprotein into MA, CA, and NC proteins in vitro [19–22].
HTLV-I protease is a small dimer composed of two iden-substrate within the active site.
Sequence alignment of several retroviral proteases is tical subunits containing 125 amino acids each. Struc-
turally, this protease shares the active site motif Asp-shown in Figure 2. They exhibit only modest homology
to one another. The regions of highest homology are Thr-Gly with other retroviral proteases and has homol-
ogy in the sequences flanking the active site. Sequencefound at the dimer interface (the N- and C-terminal re-
gions) and in the residues surrounding the catalytic alignment of retroviral proteases indicates that HTLV-I
protease is most closely related to HTLV-II protease andaspartic acid, indicated by the asterisk. There is also
significant homology in the residues that form the bind- BLV protease (Figure 2). One notable difference between
the leukemia virus proteases and the other retroviraling pockets for the substrate, which results in similarity
Figure 2. Sequence Alignment of the Leuke-
mia Retrovirus Proteases with Retroviral Pro-
teases of Known Structure
The alignment for HIV-1, HIV-2, SIV, FIV, EIAV,
and RSV proteases was generated based on
the reported structures (PDB IDs: HIV-1,
1A30; HIV-2, 1HSI; SIV, 1YTH; FIV, 1B11;
EIAV, 1FMB; and RSV, 1BAI). These struc-
tures have the following mutations from the
wild-type proteases: HIV-1: Q7K, L33I, L63I;
SIV: Q7K; EAIV: I54G; RSV: S38T, I42D, I44V,
M73V, A100L, V104T, R105P, G106V, and
S107N. Hydrophobic residues are indicated
in yellow, hydrophilic residues in green, acidic
residues in red, and basic residues in blue.
Abbreviations: BLV, bovine leukemia virus;
MuLV, murine leukemia virus; SIV, simian im-
munodeficiency virus; FIV, feline immunode-
ficiency virus; EIAV, equine infectious anemia
virus; RSV, Rous sarcoma virus.
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Table 1. Retroviral Protease Cleavage Sites
Cleavage
Junction HTLV-I BLV MuLV RSV HIV-1 FIV EIAV
MA/CA PQVL/PVMH PAIL/PIIS - VVAM/PVVI SQNY/PIVQ PQAY/PIQT SEEY/PIMI
MA/pX - - SSLY/PALT - - - -
X/CA - - SQAF/PLRA - - - -
CA/NC TKVL/VVQP PAIL/VHTP SKLL/ATVV AAAM/SSIA - KMQL/LAEL -
CA/pX - - - - ARVL/AEAM - KMML/LAKA
pX/NC - - - - ATIM/MQRG - AKAL/QTGL
NC/pX - - - - RQAN/FLGK - -
Gag/PR ASIL/PVIP LECL/LSIP TSLL/TLDD PAVS/LAMT SFNF/PQIT GFVN/YNKV QFVG/VTYN
PR/Pol PVIL/PIQA PMVG/VLDA LQVL/TLNL LTNL/IGRA TLNF/PISP RLVM/AIQS KLVL/AQLS
Pro/RT PAVL/GLEL - - - - - -
RT-RH/IN VLQL/SPAD unk unk FQAY/PLRE RKIL/FLDG CQTM/MIIE TGVF/WVEN
The scissile bond is indicated by the slash.
proteases is the presence of additional amino acids at typically required for substrate recognition, changes in
the length of the peptide substrate have a significantthe C terminus. It can be seen from the sequence align-
ment with other retroviral proteases that the leukemia effect on the kinetic parameters for cleavage. It was also
recently demonstrated that activity of HTLV-I protease isvirus proteases are the only ones that contain these
“extra” amino acids. There is a report that suggests the not dependent on the concentration of NaCl [30]. This
is in contrast to a prior report stating that a concentrationten C-terminal residues of HTLV-I protease are required
for activity, but this was based on the detection of unpro- of 0.5 M (NH4)2SO4 decreases Km by 20-fold [19]. It has
also been reported that there is an increase in proteolyticcessed Gag produced during coexpression of the dele-
tion mutant and the Gag polyprotein [23]. However, the activity upon an increased ionic strength for HIV-1 and
BLV proteases [31–33]. On the other hand, the activitymutant was not purified and tested further. On the other
hand, a BLV protease mutant in which the ten C-terminal of HIV-1 protease has been reported to be independent
of sodium ion concentration, but decreases upon anresidues were deleted has been reported and it retains
proteolytic activity [24]. Recently, a mutant of HTLV-I increase in magnesium ion concentration [31]. This is
attributed to dissociation of the homodimer because aprotease in which the ten C-terminal residues have been
removed was prepared and cleavage data indicate that red shift in tryptophan fluorescence is observed along
with an increase in quantum yield, which is indicativethis deletion has no effect on activity (S. Shuker et al.,
submitted). The function of these “extra” residues, if any, of increased solvent exposure for those residues.
Unlike HIV protease, no structures of HTLV-I proteaseis unclear, but it is evident that they are not necessary for
the proteolytic activity of these enzymes. have been reported to date. To elucidate the factors
important for the specificity of the protease, a modelMany of the natural cleavage sites for HTLV-I protease
have been identified [19, 20, 25, 26], and quantitative (Dennison, Herger, Shuker: PDB ID 1O0J) was generated
based on homology to a mutant of RSV protease, whosemeasurements of the kinetic parameters of HTLV-I pro-
tease cleavage of peptides corresponding to the MA/ structure has been reported [29, 34] (PDB ID 1BAI). Al-
though HTLV-I protease has higher homology to HIVCA, CA/NC, and PR/pX processing sites [19, 27–30], as
well as processing sites for other retroviral polyproteins protease, the protease from RSV was chosen because
fewer insertions are required and too many insertions[28, 29], have been reported (Table 2). From these data,
it can be seen that although only seven amino acids are can result in a less accurate model. While the relatively
Table 2. Kinetic Parameters for Cleavage of HTLV-I Junctions and Junctions from Other Retroviruses by HTLV-I Protease
Cleavage Junction Peptide Substrate kcat (s1) Km (M) kcat/Km (mM1s1) Ref
MA/CA APQVL/PVMHP 8.7  0.6 120  18 75 27
APQVL/PVMHP 5.9  0.6 69  20 85 28
PQVL/PVMHP 0.22  0.01 60  7 3.7 30
YVEPTAPQVL/
PVMHP 0.085 500 0.17 19
PR/p3 KGPPVIL/PIQAP 11.8  0.9 40  10 290 28
KGPPVIL/PIQAP 6.9  0.4 30  6 230 27
CA/NC KTKVL/VVQPK 5.2  0.1 33  4 160 27
KTKVL/VVQPK 7.7  0.2 51  5 150 28
KTKVL/VVQPK 10.0 63 160 29
TKVL/VVQPK 2.7 87 31 29
gag/PR DPASIL/PVIP 0.7  0.05 230  35 3.0 27
HIV-1 MA/CA VSQNY/PIVQ not cleaved 29
BLV MA/CA PPAIL/PIISE 3.3  0.2 20  6 165 28
BLV CA/NC KQPAIL/VHTPG not cleaved 28
BLV PR/pX PPVMG/VLDAP 0.010  0.001 14  4 0.7 28
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Figure 3. Homology Model of HTLV-I Protease without the Ten C-Terminal Residues
The subsites are shown in spacefilling representation (S4 and S4, top left; S3 and S3, top right; S2 and S2, bottom left; S1 and S1, bottom
right) with hydrophobic residues colored in green and hydrophilic residues colored by element. The catalytic aspartic acids are shown in
purple and the substrate is shown in orange. PDB ID of HTLV-I protease is 1O0J.
low homology to RSV protease (25%) calls into question P4 threonine with valine or leucine produces an increase
in kcat/Km due to a lower Km value. Other uncharged resi-the reliability of the finer details of the model, it is useful
for identifying residues that may be important for speci- dues cause a slight decrease in catalytic efficiency,
while replacement with aspartic acid results in a dra-ficity of the subsites, which are shown in Figure 3. In
addition, To¨zse´r and coworkers have also prepared a matic decrease in cleavage efficiency. In all cases, the
change in efficiency is due to a change in Km. Not surpris-model and have reported the effect on the kinetic param-
eters of amino acid changes in a peptide corresponding ingly, hydrophobic residues favor the association of the
substrate with the protease. Therefore, although this isto the CA/NC cleavage site (summarized in Table 3) [29].
These data, in conjunction with the homology model and a surface exposed binding pocket made up of mostly
polar or charged residues, peptides with a hydrophobiccharacterization of native HTLV-I and other retroviral
processing sites, provide insight into the specificity for amino acid at P4 are cleaved with the highest efficiency.
No substitutions have been reported for P4 in a naturalthe protease subsites.
S4 and S4 Subsites substrate.
S3 and S3 SubsitesThe S4 and S4 subsites are shallow, surface-exposed
pockets formed by residues Asp36, Met37, Asn53, Thr54, The S3 and S3 subsites are large pockets that can
accommodate a variety of side chains, as seen in theSer55, Cys90, and Val92. In the natural substrates, the
P4 and P4 positions are most often hydrophobic resi- various P3 and P3 groups found in the natural sub-
strates (alanine, valine, leucine, glutamic acid, gluta-dues, with proline being the most prevalent. A variety
of side chains are tolerated, however, including polar mine, serine, lysine; see Table 1). They are formed by a
combination of hydrophobic side chains closer to the(serine and threonine) and charged (aspartic acid and
histidine) residues. Truncation of the CA/NC peptide to protein interior (Leu30) and charged and hydrophilic side
chains at the protein surface (Arg10, Asp36, Lys95,remove the amino acid at P4 results in a decrease in
catalytic efficiency. Replacement of the native CA/NC Asn96, and Asn97). Substrate hydrophobic residues can
Review
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Table 3. Catalytic Efficiency of HTLV-I Protease Cleavage of Peptides Corresponding to the CA/NC Site with Single Amino Acid
Substitutions
Peptide Substrate kcat/Km (mM1s1) Peptide Substrate kcat/Km (mM1s1)
KTKVL/VVQPK 159 KTKVF/VVQPK 335
TKVL/VVQPK 31.0 KTKVY/VVQPK 61.6
KVL/VVQPK only slight cleavage KTKVA/VVQPK 30.0
KVKVL/VVQPK 267 KTKVM/VVQPK 27.3
KLKVL/VVQPK 210 KTKVG/VVQPK 2.2
KGKVL/VVQPK 98.6 KTKVS/VVQPK only slight cleavage
KPKVL/VVQPK 58.9 KTKVD/VVQPK not cleaved
KSKVL/VVQPK 40.0 KTKVK/VVQPK not cleaved
KAKVL/VVQPK 36.0 KTKVL/LVQPK 134
KDKVL/VVQPK 2.3 KTKVL/IVQPK 12.5
KTFVL/VVQPK 145 KTKVL/FVQPK 2.0
KTAVL/VVQPK 114 KTKVL/PVQPK 1.1
KTLVL/VVQPK 112 KTKVL/SVQPK only slight cleavage
KTVVL/VVQPK 10 KTKVL/GVQPK not cleaved
KTSVL/VVQPK 38.9 KTKVL/DVQPK not cleaved











interact with the interior, hydrophobic portion of the HTLV-I protease. No substitutions have been reported
for the P2 position, but it is evident from examinationbinding site, while hydrophilic residues can interact with
the more polar groups near the surface. Although the of the natural substrates that hydrophobic residues are
preferred. The only peptide with a charged residue atnatural amino acid in the P3 position in the CA/NC pep-
tide is a lysine, peptides with hydrophobic residues such P2 whose incubation with HTLV-I protease has been
reported is the BLV CA/NC substrate KQPAIL/VHTPG,as phenylalanine, leucine, and valine in this position
are cleaved with almost the same catalytic efficiency. and no cleavage is observed for this peptide. It is clear
that hydrophobic residues are the preferred residues inSubstitution with an aspartic acid, serine, or glycine at
the P3 position, however, causes a decrease in activity. the P2 and P2 positions.
S1 SubsiteInterestingly, an acidic residue is found at P3 in the
natural pX/RT cleavage site and the BLV PR/pX junction The S1 subsite is hydrophobic and is formed by residues
Arg10, Leu30, Gly34, Val56, Leu57, Gln96, Gln97, Trp98,PPVMG/VLDAP is cleaved by HTLV-I protease. No sub-
stitutions have been reported for the P3 position; and Ile100. All of the natural substrates for HTLV-I prote-
ase have a leucine in the P1 position and amino acidshowever, inspection of the natural substrates and other
polyprotein junctions that have been cleaved with with a -branch are not accommodated [27]. The P1
position is quite sensitive to substitution, and replace-HTLV-I protease reveals that a variety of side chains are
accommodated. The P3 and P3 positions appear to be ment of the P1 leucine with a charged amino acid results
in loss of cleavage while replacement with hydrophilicthe most tolerant to a variety of different side chains,
and charged amino acids in the native substrates are serine gives a peptide that shows only slight cleavage
when incubated with the protease. Replacement with amost often found in these positions.
S2 and S2 Subsites phenylalanine gives an increase in kcat/Km, while other
hydrophobic residues reduce the catalytic efficiency.The S2 and S2 subsites are large, hydrophobic pockets
that accommodate aliphatic groups in the natural sub- The presence of a leucine at this position appears to be
one of the critical factors for the specificity of HTLV-Istrates, particularly the -branched residues valine and
isoleucine. They are formed by predominately hydropho- protease.
S1 Subsitebic side chains (Ala35, Asp36, Met37, Val39, Thr54, Val56,
Leu57, Val92, and Ile100). For the CA/NC peptide, the The S1 subsite most often accommodates proline in
natural HTLV-I substrates. Replacement of the nativeP2 position is much less tolerant to substitution than
P3 or P4, and replacement of the native valine with CA/NC P1 valine with a leucine has little effect on kcat/Km,
but all of the other reported substitutions result in lessleucine is the only reported substitution that does not
cause a dramatic drop in kcat/Km. Substitution with efficient cleavage. As with the P2 and P1 positions,
substitution with charged or hydrophilic residues resultscharged or hydrophilic residues results in peptides that
are not cleaved by the protease. Consistent with this is in peptides that either are not cleaved or show only
slight cleavage when incubated with the protease. Thisthe observation that the HIV MA/CA peptide VSQNY/
PIVQ, which has an asparagine at P2, is not cleaved by is in contrast to recent reports identifying new cleavage
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Table 4. Ki Values for Compounds that Have Been Tested for Inhibition of HTLV-I Protease
Ki (M)
Inhibitor Structure HTLV-I HIV-1 Ref
DMP-323 10 0.0003 27
MES13-099 0.24 0.007 35
LP-149 10 0.0017 27
UK-88,897 10 0.012 27
Ro-31-8959 10 0.0004 27
N-1270 Arg-Val-Leu*-Phe-Glu-Ala-Nle-NH2a 127 0.050 35
N-1465 Ac-Thr-Ile-Nle*-Nle-Gln-Arga 12.7 0.78 35
N-1460 Ser-Gln-Asn-Phe*-Pro-Ile-Val-Glna 7.3 1.0 35
1 Boc-Val-Val-Phe(PC)Phe-Val-Val-NH2b 0.080 0.0004 27
JG-365 Ac-Ser-Leu-Asn-Phe-CH(OH)CH2NH-Pro-Ile-Val-OMe 0.006 0.00066 35
2 Lys-Thr-Lys-Val-Sta-Val-Gln-Pro-Lys 10 10 27
3 Pro-Pro-Cys-Val-Phe-Sta-Ala-Met-Thr-Met 10 NDc 27
4 Pro-Tyr-Val-Phe-Sta-Ala-Met-Thr 10 12.5 27
5 Ala-Pro-Gln-Val-Sta-Val-Met-His-Pro 0.050 0.13 27
6 Ac-Pro-Gln-Ile-Thr-Leu-Trp-Gln-Arg-Pro-NH2 1700 IC50  2000 22
7 Ac-Thr-Leu-Asn-Phe 252 IC50  1500 22
8 Ac-Thr-Val-Ser-Phe-Asn-Phe 217 6.1 22
N-1395 Ac-Leu-Val-Phe-H 93 IC50  0.90 35
9 Pro-Val-Ile-Pro-Leu-Asp-Pro-Ala-Arg-Arg-Pro-Val 87.2 17.1 22
10 Gln-Met-Gln-Gly-Val-Leu-Tyr-Leu 70.0 IC50  400 22
11 Ac-Leu-Lys-Ala-Gln-Ile-His-Phe 50.6 no inhibition 22
12 Tyr-Leu-Pro-Glu-Ala-Lys-Arg-Pro-Pro-Val-Ile-Leu 5.7 84 22
a Asterisk denotes a reduced peptide bond.
b PC denotes replacement of the amide bond with -P(O)(OH)- .
c ND  not determined
sites that contain a serine or glycine in this position. processing sites that have been identified. Indeed, upon
standing in solution, the protease will undergo self-Interestingly, substitution of the CA/NC P1 valine with
a proline also results in less efficient cleavage, even cleavage at this position to produce inactive fragments.
The mutation of leucine 40 to an isoleucine preventsthough proline is the most prevalent P1 amino acid in
the other natural substrates. Clearly, the surrounding autoproteolysis because -branched amino acids are
not accommodated within the S1 subsite and a moreresidues in the peptide substrate have an impact on the
interactions of a particular side chain with the protease. stable recombinant protease is provided [27]. Measure-
ment of the kinetic parameters of the L40I mutant dem-Identification of residues that form the substrate bind-
ing pockets in the model provides insight into the inter- onstrates that this mutation has no effect on the cleav-
age efficiency of natural substrates. The C90A andactions that may be responsible for the specificity of
the protease and suggest mutations that can be made C109A mutants were also prepared to form a more sta-
ble protease [27]. These residues are not believed toto test the importance of each residue. However, no
active site mutants have yet been reported. The only be involved in the formation of structurally important
disulfide bonds, and removing them was expected tomutants that have been described to date are L40I,
C90A, and C109A [27, 35]. In the protease primary se- yield protease that would be more amenable to structure
determination due to elimination of potential unwantedquence, leucine 40 is immediately followed by a proline,
and examination of the surrounding residues, ...MTVL/ disulfide bond formation. These mutations also had little
effect on the kinetic parameters of cleavage.PIAL..., show that this sequence is very similar to the
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Inhibitors of HTLV-I Protease lieved to be involved with formation of the dimer inter-
face. Surprisingly, the most active peptide in this classAt the present time, there is no effective treatment for
adult T cell leukemia and HTLV-I infection. For HIV-1 is the one corresponding to the C terminus of full-length
HTLV-I protease. Because it is unlikely that this regioninfection, there has been great success with the use of
HIV-1 protease inhibitors. Some of these inhibitors have of the protease is important for interactions at the dimer
interface, the activity of this peptide may not involve thealso been tested on HTLV-I protease; however, differ-
ences in the amino acid sequences of HTLV-I and HIV-1 disruption of the dimer but may result from binding of
the peptide in the active site. The inhibition was notprotease produce differences in susceptibilities to these
inhibitors. Table 4 summarizes what has been reported further characterized as competitive or noncompetitive,
and more work will be required to determine the modeon the inhibition of HTLV-I protease [22, 27, 36]. The
compounds MES13-099 and DMP-323 are nonpeptide of action of these peptides.
In addition to the studies described herein, it has beeninhibitors, while all of the others are peptides or modified
peptides. MES13-099 has a Ki for HTLV-I protease that demonstrated that the HIV-1 protease inhibitors ap-
proved for use in therapy fail to block HTLV-I proteaseis submicromolar, while DMP-323 shows no measurable
inhibition. However, MES13-099 is two orders of magni- Gag processing in vitro [37]. Combination chemothera-
pies have been tested in vivo but have had limited impacttude more potent against HIV-1 protease. Of the modi-
fied peptide inhibitors (LP-149, UK-88,947, Ro-31-8959, on the 7- to 18-month median survival time of individuals
with the acute form of ATL, which is the most prevalentN-1270, N-1465, N-1460, entry 1, and JG-365), two (entry
1 and JG-365) have submicromolar Ki’s, but again both form [38]. Clearly, much remains to be done in the devel-
opment of treatments for adult T cell leukemia, and moreare more potent against HIV-1 protease. The best inhibi-
tor of HTLV-I protease reported to date is JG-365, which generally, for HTLV-I infection before the onset of ATL.
Based on the success of HIV protease inhibitors andis the peptide-based compound Ac-SLNF(CH(OH)CH2N-
H)PIV-OMe. This predominantly hydrophobic molecule the low mutation rate of HTLV-I protease [39], HTLV-I
protease is a promising target for chemotherapy.has substitution that places a phenylalanine in the S1
subsite and a proline in the S1 subsite. As discussed
in the previous section, a phenylalanine in the P1 posi- Conclusions and Outlook
tion or a proline in the P1 position typically results in HTLV-I has been identified as a dangerous emerging
peptides that make excellent substrates for the prote- pathogen and it is estimated that 20 million people
ase, and inhibition of the protease by JG-365 is consis- worldwide are infected with this retrovirus. This is a
tent with this analysis of the active site binding pockets. significant problem because there are no effective treat-
Several peptide-based inhibitors incorporating the ments to control HTLV-I infection or to prevent or treat
amino acid statine, an isosteric mimetic of the tetrahe- HTLV-I-induced ATL and TSP/HAM. The protease from
dral intermediate of aspartyl protease-catalyzed peptide HTLV-I, which produces the mature structural proteins
cleavage, have also been tested. The statine isobutyl and enzymes essential for viral replication, is an
side chain binds in the S1 subsite, analogous to the P1 attractive target for inhibitor design. However, HTLV-I
leucine. Two of the peptides tested were designed to protease and its enzymology are just beginning to be
mimic HTLV-I cleavage sites: entry 5, APQV(Sta)VMHP investigated. Comparison of HTLV-I to other retroviral
(for the MA/CA junction) and entry 2, KTKV(Sta)VQPK proteases reveals significant differences in amino acid
(for the CA/NC junction). The APQV(Sta)VMHP peptide sequence, substrate specificity, and response to prote-
shows good inhibition, with a Ki of 50 nM, while the CA/ ase inhibitors. It is clear that while certain generaliza-
NC mimic has no detectable inhibition. The other statine- tions can be made among the retroviral proteases,
containing peptides tested correspond to a Mason- HTLV-I protease has features that make it distinct and
Pfizer monkey virus protease cleavage site (entry 4) or impart unique characteristics to its activity. The research
an avian myeloblastosis virus protease cleavage site described in this review lays the foundation for further
(entry 3) and neither inhibit HTLV-I protease, although work that will delineate the important structural features
both are potent inhibitors of their respective proteases. of the enzyme, define the specificity of substrate and
The final group of compounds listed in Table 4 is a set inhibitor binding within the active site, and ultimately
of peptides that corresponds to the N or C termini of lead to the development of potent and specific HTLV-I
retroviral proteases. Because the protease homodimer protease inhibitors.
is formed by interactions between the N and C termini,
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